MadeMed Review

IDL Health LLC doing business as MadeMed operates the non-clinical platform. Current terms name Xpedicare, LLC as the independent medical group responsible for care and all prescribing decisions. MadeMed does not guarantee a prescription and says its clinicians do not prescribe DEA-controlled substances.

Xpedicare, LLC is an active Florida entity whose public record names Thai Pham among its authorized members. MadeMed identifies Dr. Pham as a physician leader. NPPES returns an active exact-name Internal Medicine record, NPI 1306869466, at the Xpedicare address with Florida license ME0074845. That verifies identity, not the clinician assigned to every intake or board-certification status.

Current terms identify AbsoluteRx as a partner pharmacy and allow a patient to request transmission to another pharmacy. NPPES verifies active community or retail pharmacy record 1366987802 for AbsoluteRx Pharmacy Inc. Marketing pages separately mention Red Rock Pharmacy and a broader accredited-pharmacy network. The pharmacy notice and label should identify the actual dispenser.

The care flow is a secure online health questionnaire followed by asynchronous review from a U.S.-licensed physician. MadeMed says no routine video call is required and provides secure messaging after intake. The clinician may approve, decline, request laboratory results, change the selected treatment, or recommend care outside the platform.

Most products offer quarterly and six-month subscriptions billed at the beginning of the term. Injectable and oral GLP-1 products are described as shipping every two months, while sermorelin and NAD+ pages describe monthly shipments. The sexual-health troche ships monthly under monthly, quarterly, or annual billing.

Injectable semaglutide costs $717 for three months or $1,194 for six months. The effective monthly rates of $239 and $199 average to Avg. $219/mo. The current specific product page says L-carnitine is included, while the weight-loss catalog says B12, so the formulation is not settled enough for a canonical semaglutide card.

The semaglutide page also contains material copied or incorrect clinical text. It describes semaglutide as a dual GLP-1 and GIP agonist, uses tirzepatide-style starting and maximum doses, and compares semaglutide with itself. Those statements are not carried into this review, and the product score reflects the verification burden.

Oral semaglutide plus B6 costs $657 for three months or $1,074 for six months, averaging Avg. $199/mo. The page describes daily sublingual tablets in 1, 2, 3, or 6 mg strengths and says sixty tablets ship every two months. This compounded route and B6 combination do not match a plain semaglutide card.

Injectable tirzepatide plus L-carnitine costs $1,197 for three months or $2,214 for six months. The $399 and $369 effective rates average to Avg. $384/mo. All listed doses use the same price, but the additive means the program is not an exact plain-tirzepatide match.

Oral tirzepatide costs $897 for three months or $1,674 for six months, averaging Avg. $289/mo. The page describes daily sublingual tablets in 3, 4, 5, or 7 mg strengths. A compounded sublingual tablet is not an FDA-approved tirzepatide dosage form and does not match the current AllyRx injection or drop record.

The sexual-health formula is $119 month-to-month, $267 prepaid for three months, or $588 prepaid for twelve months. The $119, $89, and $49 monthly rates average to Avg. $86/mo. Each shipment contains eight troches with either 5 mg or 20 mg tadalafil, plus PT-141 and oxytocin, but the latter two strengths are not published.

The full three-ingredient troche is compounded and not FDA approved. MadeMed says PT-141 is FDA approved for low desire, but the FDA-approved bremelanotide product is a 1.75 mg subcutaneous injection for acquired generalized HSDD in premenopausal women. Its label says it is not indicated for men, postmenopausal women, or enhancement of sexual performance. Approval does not transfer to this sublingual combination.

Injectable sermorelin is a 9 mg per 3 mL vial described as a thirty-day supply. The $537 three-month and $1,014 six-month totals produce rates of $179 and $169 and an Avg. $174/mo card. It maps to the exact compounded injection record, while the required IGF-1 test remains a separate unpriced cost.

Oral sermorelin is described as a 1,000 mcg daily sublingual tablet. It costs $327 for three months or $594 for six months, averaging Avg. $104/mo. The oral route remains editorial-only because the current reusable sermorelin record is an injection.

Injectable NAD+ supplies 1,000 mg per month across eight subcutaneous injections. The $627 three-month and $1,194 six-month totals produce rates of $209 and $199 and an Avg. $204/mo card. A comprehensive metabolic panel is required before prescribing.

NAD+ nasal spray is labeled 500 mg per mL in a 15 mL, 7,500 mg bottle for thirty days. It costs $837 for three months or $1,614 for six months, averaging Avg. $274/mo. The route is editorial-only, and the page headline says from $279 even though its own six-month rate is $269.

Injectable sermorelin requires an IGF-1 test. Both NAD+ routes require a comprehensive metabolic panel for kidney and liver function. MadeMed accepts results from a CLIA-certified laboratory completed within six months and directs patients to Quest or Labcorp when new testing is needed. No test price or included-lab statement is public.

MadeMed's general list and several treatment pages name forty service states, excluding Alabama, Alaska, Arkansas, Hawaii, Massachusetts, Missouri, New Mexico, New York, South Carolina, and Virginia. Injectable GLP-1 and NAD+ pages instead list twenty-three states that include Missouri, New Mexico, and New York while excluding many general-list states. Oral sermorelin has no public state answer.

Current product FAQs describe a $39 quarterly consultation fee included in the displayed price. It covers review, continuing dosage adjustments, and oversight. If the physician declines a prescription, MadeMed says it refunds the payment minus $39. The returns policy separately says completed consultation fees are nonrefundable.

Subscriptions renew until cancelled. Product FAQs say MadeMed emails the exact amount seven days before every charge and offers pause, skip, or cancellation controls. Cancellation is available in the account dashboard or through support email, becomes effective at the end of the current billing period, and does not produce a prorated refund.

Prescription and over-the-counter sales are final after pharmacy dispensing. A consultation cancelled with less than twenty-four hours' notice may not qualify for a refund. Damaged, incorrect, or lost orders must be reported within seven days with the order number and, when relevant, photographs; MadeMed may replace or refund the affected product.

All current product pages advertise free discreet shipping. Injectable GLP-1 pages add overnight, temperature-controlled delivery and supplies. Oral GLP-1 pages say a thirty-day supply arrives, while their billing blocks describe sixty tablets shipped every two months. That quantity conflict should be resolved in the order confirmation.

Support is available by email at support@mademed.com, phone at +1 (800) 582-1428, web form, patient portal, and secure clinical messaging. MadeMed markets real-human support and sends billing reminders, but it does not publish support hours, response-time targets, or an emergency clinical channel. The service directs emergencies to 911.

MadeMed is cash pay and says it does not accept insurance, HSA cards, or FSA cards. Its terms distinguish non-clinical account and payment data from protected health information handled for Xpedicare. The privacy policy permits sharing with marketing and advertising partners that may count as a sale or sharing under some state laws and provides opt-out rights.

Compounded semaglutide, tirzepatide, sermorelin, NAD+, and the sexual-health combination are not FDA approved. FDA does not review compounded prescriptions before marketing for safety, effectiveness, or quality. An active pharmacy license, LegitScript badge, or claimed laboratory test does not approve an individual product.

FDA currently says semaglutide and tirzepatide are not on the shortage list and explains restrictions on routine compounding of products that are essentially copies of commercially available drugs. The patient-specific prescription and pharmacy are necessary to understand the legal basis and exact formulation of a compounded GLP-1 order.

Several product pages import weight-loss percentages and trial names from FDA-approved drug research into MadeMed's compounded programs without demonstrating that the exact additive, route, dose, and formulation were studied. The semaglutide page's copied tirzepatide mechanics make those marketing sections unreliable.

MadeMed claims third-party potency verification, comprehensive sterility testing, extended stability, exclusive additives, and broad clinical benefits. The current public pages do not provide certificates, laboratory identities, batch records, protocols, or direct evidence for those exact claims. They are not treated as verified product-quality findings.

Product pages display ratings between 4.1 and 4.9 out of 5 and several testimonials without a visible review count, collection method, moderation policy, or source record. AllyRx does not convert those figures into a user rating or represent the testimonials as independently verified outcomes.

The Katalys application is pending under offer 1536. The network published a partial payout range from $78 to $400 across treatments or bundles and a discovery EPC of $0.00. No tracking URL or affiliate-compatible customer promotion has been issued, so the unpublished CTA uses the canonical MadeMed domain without a promo line.